Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2021 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital

FLORHAM PARK, N.J., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
September 08, 2021 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

FLORHAM PARK, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
August 31, 2021 07:45 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

FLORHAM PARK, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
August 10, 2021 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones

Pivotal Phase 3 PHALCON-EE trial topline data for vonoprazan in erosive esophagitis expected in October 2021Phase 2 PHALCON-NERD on-demand trial for vonoprazan in non-erosive reflux disease enrolling...
August 05, 2021 07:30 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.

FLORHAM PARK, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
August 02, 2021 08:30 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI

FLORHAM PARK, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
May 25, 2021 16:01 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

FLORHAM PARK, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
May 11, 2021 08:00 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates

Positive Phase 3 trial of vonoprazan in Helicobacter pylori (H. pylori) infection; New Drug Applications (NDAs) targeted for the fourth quarter of 2021U.S. Food and Drug Administration (FDA) grants...
May 06, 2021 17:48 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

FLORHAM PARK, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel...
April 29, 2021 16:01 ET | Source: Phathom Pharmaceuticals

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints

Both vonoprazan-based treatment regimens demonstrated superior eradication rates vs. a standard of care proton pump inhibitor (PPI)-based triple therapyNew Drug Application (NDA) submissions targeted...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right